Breaking News

Alvogen Acquires Naprelan from Shionogi

November 7, 2013

Gains exclusive rights in the U.S. to naproxen product

Alvogen Pharma US, Inc. has acquired from Shionogi Inc., exclusive rights to commercialize Naprelan (naproxen sodium) controlled-release tablets, 375 mg, 500 mg, and 750 mg, in the U.S. Naprelan is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout, as well as the relief of mild to moderate pain, and the treatment of primary dysmenorrhea. The product will be marketed by Alvogen’s subsidiary, Almatica Pharma, Inc.
Alvogen also acquired all rights and interest in the NDA for Naprelan from Stat-Trade, Inc. According to IMS Health data, Naprelan had annual U.S. sales of $58 million in 2012.
“Alvogen’s acquisition of Naprelan delivers on yet another strategic objective by further strengthening and diversifying our growing branded portfolio in the U.S. market,” said Darren Alkins, president, Alvogen Americas.

blog comments powered by Disqus